A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer

Maria Q. Baggstrom, Yingwei Qi, Marianna Koczywas, Athanassios Argiris, Elizabeth A. Johnson, Michael J. Millward, Sara C. Murphy, Charles Erlichman, Charles M. Rudin, Ramaswamy Govindan

Research output: Contribution to journalArticlepeer-review

Abstract

Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence

Original languageEnglish (US)
Pages (from-to)1757-1760
Number of pages4
JournalJournal of Thoracic Oncology
Volume6
Issue number10
DOIs
StatePublished - Oct 2011

Keywords

  • AT-101
  • Extensive-stage small cell lung cancer
  • Gossypol

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer'. Together they form a unique fingerprint.

Cite this